after an initial 4-week treatment with once-daily Enstilar Foam. Patients were randomized to receive either Enstilar Foam or vehicle twice-weekly on 2 non-consecutive days for up to 52 additional ...

The long-term, vehicle-controlled, double-blind, phase 3 PSO-LONG trial compared twice-weekly Enstilar foam (calcipotriene ... The number of days before 75% of subjects experienced relapse was ...

The FDA has approved Leo Pharma’s Enstilar foam for the treatment of plaque psoriasis. The approval comes on the back of a clinical trial that showed patients achieved significant degrees of ...

LEO Pharma has launched Enstilar ... with foam spray achieved a 75 per cent improvement in modified (excluding head) Psoriasis Area and Severity Index (mPASI) score from baseline after four ...

The FDA has expanded the approval for Taclonex Topical Suspension and Enstilar Foam, two plaque psoriasis therapies to include younger patients. The Food and Drug Administration (FDA) has expanded ...

Adult patients with plaque psoriasis have gained a new treatment option in the UK following the launch of LEO Pharma's Enstilar, the first fixed-combination, cutaneous foam spray for topical ... using ...